VISCHER advised Ikerian on the deal. Ikerian AG and its subsidiary, RetinAI U.S. Inc., a leading developer of software solutions for medical image and data management,...
Ikerian’s $8 Million Series B Financing Round
Straumann Group’s Acquisition Of Mininavident AG
VISCHER advised Mininavident AG on the deal. Mininavident AG, in Liestal, developer and manufacturer of the world’s smallest dynamic navigation system for dental implant placement, was...
Memo Therapeutics AG’s CHF20 Million Additional Series C Financing Round
VISCHER advised Ysios Capital and Kurma Partners. Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised...
Odne’s $5.5 Million Financing Round
VISCHER AG acted for Odne on the deal. Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch for...
Artiria Medical SA’s CHF6 Million Series A2 Financing Round
VISCHER acted for Artiria Medical SA on the deal. Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation neuro-interventional products for stroke and aneurysms, closed...
GlycoEra’s Incresing Its Series A Financing Round
Vischer advised GlycoEra AG on the deal. GlycoEra AG has closed CHF 45m (USD 49m) Series A financing round, co-led by re-nowned US and European life...
Proteomedix and Blue Water Biotech’s Forms Onconetix
VISCHER advised Proteomedix on the deal. Proteomedix AG, a Swiss private, commercial-stage diagnostics oncology company and Water Biotech, Inc. (Nasdaq: BWV) are forming together a company...
Nouscom’s €67.5 Million Oversuscribed Series C Financing Round
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
Memo Therapeutics AG’s CHF25 Million Series C Financing Round
VISCHER advised Memo Therapeutics on the financing. Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round...
LimmaTech Biologics AG’s $37 Million Series A Financing Round
VISCHER acted as legal advisor to LimmaTech Biologics in the transaction. LimmaTech Biologics AG closed a USD 37m (CHF 33m) Series A financing round co-led by Adjuvant...
Mosanna Therapeutics’s Seed Financing Round Extension
VISCHER advises Mosanna Therapeutics on the deal. Mosanna Therapeutics AG closes an extension of the Seed Financing Round with the investors Supermoon Capital and High-Tech Gründerfonds...
Bachem’s CHF 108.1 Million Accelerated Bookbuilding Process
VISCHER AG advises Bachem Holding on the offering. Bachem Holding AG (SIX: BANB) has successfully raised CHF 108.1 million through the placement of 1’250’000 new registered...